media – Page 11 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Another biotech company goes bankrupt

Recently, US biotechnology company Nido Biosciences announced via LinkedIn that it is officially ceasing operations because its core pipeline , NIDO-361 , failed to meet its primary endpoint in a global Phase 2 clinical trial . Biotech, which had received $109 million in funding from institutions such as Eli Lilly and was hailed as “the most promising next-generation biotech startup,” ultimately failed at the finish line of its Phase 2 clinical trial. 01 The Fall of a Star Biotech Founded in 2020 and incubated by renowned venture capital firm 5AM Ventures, Nido Biosciences focuses on developing innovative drugs to treat neurological diseases. Its core product, NIDO-361, targets spinal bulbar muscular atrophy (SBMA, also known as Kennedy’s disease), a rare X-linked recessive neuromuscular disease that primarily affects adult men, with an incidence rate of 1-2.5 per 100,000. In 2023, Nido Biosciences completed its Series A funding round, co-led by 5AM Ventures, ...
- Source: drugdu
- 69
- January 27, 2026
Green Bamboo Biotechnology’s LZ901 vaccine is about to be launched, reshaping the shingles vaccine market landscape.

From a capital market perspective, innovative breakthroughs and commercialization in the vaccine sector remain the core value anchors. With the domestic shingles vaccine market penetration rate below 1% and price wars forcing industry upgrades, Green Bamboo Biotechnology (02480.HK) ‘s core product, the recombinant shingles vaccine LZ901, is nearing its market launch. This world’s first recombinant vaccine with a tetrameric molecular structure, with its differentiated clinical advantages and product characteristics tailored to market demands, is not only expected to become a core driver for the company’s commercialization but will also bring new value growth points to the vaccine sector in the capital market, reshaping the competitive and value landscape of the domestic shingles vaccine market. The blue ocean potential of the shingles vaccine market has long been recognized by the capital market. Data shows that China has over 700 million people aged 40 and above, and 320 million elderly people aged ...
- Source: drugdu
- 64
- January 27, 2026
MEDEXPO Kenya

Organiser：EXPOGROUP Time：April 22 -24, 2026 Address：P.O. Box 30746-00100 Harambee Avenue, Nairobi, Kenya Exhibition hall： Kenyatta International Conference Centre Product range: Medical Equipment: Anesthesia equipment, respiratory equipment, imaging equipment, blood pressure equipment, diagnostic instruments and devices, dialysis equipment, electro (high-frequency) therapy equipment, surgical instruments, electroencephalographs, electrocardiogram (ECG) equipment and accessories, ultraviolet and infrared radiation equipment, laboratory supplies, ultrasonic diagnostic equipment, cardiac catheterization equipment, infusion technology equipment, magnetic resonance imaging scanning equipment, laser therapy, surgical equipment, etc. Dental Equipment: Dental instruments and equipment, maintenance and repair services, filling materials, radiological equipment and products, sterilization systems, dental care products. Optical Equipment: Ophthalmic testing equipment, optical and sunglass frames, lens frames and manufacturing equipment and accessories, optical instruments and components. Healthcare Products: Medical herbal preparations, food supplements, vitamins and minerals, diet and nutrition products, personal hygiene products, homeopathic preparations, dermatological preparations, mother and baby care products, baby food, fitness equipment, and other healthcare-related ...
- Source: drugdu
- 61
- January 27, 2026
Flunotinib maleate receives Breakthrough Therapy Designation

Recently, Chengdu Zeling Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as “Zeling Bio”) announced that its independently developed core product, Flunotinib Maleate Tablets (FM), has been officially included in the Breakthrough Therapy Designation (BTD) program by the Center for Drug Evaluation (CDE) of the National Medical Products Administration . The proposed indication is BCR-ABL fusion gene (Ph) negative myeloproliferative neoplasms (MPN), including myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). BTD demonstrates clinical value and accelerates drug development. The Breakthrough Therapy Program (BTD) is a special review pathway established by the National Medical Products Administration (NMPA) to accelerate the research and development and market launch of innovative drugs with significant clinical advantages. It aims to expedite the development of innovative drugs for the prevention and treatment of serious life-threatening or life-threatening conditions for which there are currently no effective treatments or which offer significant clinical advantages compared to existing ...
- Source: drugdu
- 65
- January 26, 2026
The National Medical Products Administration (NMPA) has conditionally approved the marketing of ribevirtadalafil injection.

Recently, the National Medical Products Administration (NMPA) conditionally approved the marketing of ribevirtadalafil injection (trade name: Huayounuo) submitted by Huahui Anjian (Beijing) Biotechnology Co., Ltd. through the priority review and approval procedure. The injection is indicated for the treatment of adult patients with chronic hepatitis D virus (HDV) infection, with or without compensated cirrhosis. The approval of this product provides a new treatment option for these patients. https://mp.weixin.qq.com/s/csXAJrCcig_shh8wQKyhIQ
- Source: drugdu
- 64
- January 26, 2026
Zhongsheng Pharmaceutical Subsidiary Receives Clinical Trial Approval for New Indication of Class 1 Innovative Drug RAY1225 Injection

Beijing Business Today News – On the evening of January 23, Zhongsheng Pharmaceutical (002317) released an announcement stating that its holding subsidiary, Guangdong Zhongsheng Ruichuang Biological Technology Co., Ltd. (hereinafter referred to as “Zhongsheng Ruichuang”), has received approval from the National Medical Products Administration (NMPA) for a Phase III clinical trial of its self-developed Class 1 innovative peptide drug, RAY1225 Injection. The approval, confirmed via the “Drug Clinical Trial Approval Notice,” covers a new indication: the treatment of “obesity comorbid with obstructive sleep apnea (OSA).” According to the announcement, RAY1225 Injection is an innovatively structured peptide drug with global independent intellectual property rights developed by Zhongsheng Ruichuang. It functions as a dual GLP-1 (Glucagon-like peptide-1) receptor and GIP (Glucose-dependent insulinotropic polypeptide) receptor agonist. Benefiting from its superior pharmacokinetic profile, the drug demonstrates ultra-long-acting potential, supporting a convenient once-every-two-weeks dosing schedule. https://finance.eastmoney.com/a/202601233629301734.html
- Source: drugdu
- 62
- January 26, 2026
Revenue Up 72.57%, HIV Innovative Drug Sales Surge 90.34%

On January 25, Aidea Pharmaceutical (688488.SH) officially released its 2025 annual earnings forecast. During the reporting period, the company maintained strong momentum, achieving “rapid revenue growth and a significant narrowing of losses.” This stellar performance highlights the rising competitiveness of its core business and the effectiveness of its “HIV Innovative Drugs + Human Protein” dual-engine strategy, injecting solid momentum into high-quality, long-term sustainable growth. According to preliminary calculations by the finance department, the company’s 2025 performance saw steady climbs across several key financial indicators: Leapfrog Growth in Revenue Scale Total annual revenue is expected to reach approximately 721.01 million RMB, an increase of about 303.21 million RMB compared to the previous year. This represents a year-on-year (YoY) increase of 72.57%, demonstrating the company’s robust capacity for strategic execution and market expansion. Core Products Continue to Lead The anti-HIV innovative drug business, serving as the core growth engine, performed exceptionally well. ...
- Source: drugdu
- 69
- January 26, 2026
ASC30 Completes First Dosing in US Phase II Clinical Trial for Diabetes Treatment

On January 26, Ascletis Pharma (01672) announced that it had completed dosing of the first subjects in its Phase II US study of the oral small molecule GLP-1R agonist ASC30 for the treatment of diabetes. Top-line data from the study are expected to be available in the third quarter of 2026. A 13-week study in obese or overweight subjects showed that ASC30 resulted in a placebo-adjusted weight loss of up to 7.7%, with better gastrointestinal tolerability and no liver safety signals observed. The study enrolled 125 obese subjects or overweight subjects with at least one weight-related comorbidity. At the primary endpoint of week 13, once-daily doses of ASC30 tablets at 20 mg, 40 mg, and 60 mg resulted in weight loss of 5.4%, 7.0%, and 7.7%, respectively, which were statistically significant and clinically meaningful. The overall discontinuation rate due to adverse events was 4.8%. ASC30 is the first small molecule ...
- Source: drugdu
- 55
- January 26, 2026
Johnson & Johnson projects its revenue will reach $100 billion by 2026.

Today, Johnson & Johnson released its 2025 financial results. Full-year revenue reached $94.2 billion, a 6.0% increase year-over-year ; net income reached $26.8 billion, with diluted earnings per share (EPS) of $11.03, a 90.5% increase year-over-year; adjusted EPS was $10.79, an 8.1% increase year-over-year. Johnson & Johnson Chairman and CEO Joaquin Duato stated that 2025 will be a pivotal year for the company, marking the beginning of a new era of accelerated growth. The company projects its sales will reach $100 billion by 2026 . In 2022, Pfizer became the first biopharmaceutical company to reach $100 billion in annual revenue. However, since COVID-19 products accounted for more than half of its sales, its revenue surge lasted only one year. Four years later, Johnson & Johnson is also about to reach the $100 billion milestone, and this achievement seems to be more sustainable. Johnson & Johnson’s current business consists of two ...
- Source: drugdu
- 82
- January 26, 2026
Eli Lilly’s “miracle weight-loss drug” targets a new trillion-dollar market; is it about to revolutionize the liver disease treatment landscape?

Recently, according to the CDE (Center for Drug Evaluation) website, Eli Lilly’s GIP/GLP-1 dual receptor agonist, “Telborpeptide Injection,” is proposed for inclusion in the Breakthrough Therapy designation for the treatment of metabolic-associated fatty liver disease (MASH). This marks the fourth major market for Telborpeptide in China. Previously, it has been approved in China for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea. This proposed inclusion in the Breakthrough Therapy designation signifies its significant advantages in treating MASH, and its market launch is expected to be significantly accelerated. MASH is a serious chronic liver disease caused by excessive fat accumulation in the liver, leading to inflammation and fibrosis. Approximately one-third of overweight or obese individuals may have MASH. However, the path to drug development for MASH has been exceptionally arduous, with a complex pathogenesis that has caused numerous pharmaceutical giants to fail over the past few decades, ...
- Source: drugdu
- 114
- January 26, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.